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Results: After MCA-SSH and DS, 117 clones from a total of 1000 
were selected for sequence analysis. Four genes were identiﬁed in the 
DNA fragments from 117 clones from A/J mouse lung tumor tissue. 
These were KIF21A (kinesin family member 21A), Samd14 (sterile 
alpha motif domain containing 14), EG436235 (similar to regulator of 
G-protein signal 3) and Vwa1 (von Willebrand factor A domain con-
taining 1). Among these four genes, two gene fragments had a genomic 
region that met the criteria for a CpG island. RT-PCR showed differ-
ences in expression level between A/J mouse normal lung tissue and 
lung adenoma tissue for the KIF21A (p<0.005), Samd14 (p=0.005) and 
EG436235 (p<0.01) genes. Further study of the human homologues 
of KIF21A (p<0.01) and Samd14 (p<0.002) showed that they were 
expressed in normal lung tissue but markedly down-regulated in lung 
adenocarcinoma tissue. Bisulﬁte sequencing revealed that the prom-
tor region of Samd14 in human lung adenocarcinoma was methylated 
more frequently than that of its normal counterpart.
Conclusions: The expression level of the KIF21A (location: 12q12) 
and Samd14 (location: 17q21.33) genes is down regulated in human 
pulmonary adenocarcinoma tissue. The methylation frequency of the 
Samd14 gene in the promotor region is higher in human pulmonary 
adenocarcinoma than in normal lung tissue. These data suggest that 
promotor methylation of these genes is a speciﬁc event in pulmonary 
adenocarcinogenesis, and that their down-regulation may be function-
ally associated with malignant progression of lung adenocarcinoma
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Introduction: A novel approach has been developed for the prediction 
of major NSCLC classes and the prediction of patient outcome based 
on gene expression. To achieve this, bronchial and lung biopsies taken 
at the time of diagnosis were processed on a high-sensitivity microar-
ray platform.
Methods: Microarray proﬁling was performed using the NovaChip® 
array platform. Samples were lung and bronchoscopic biopsies from 61 
NSCLC patients (24 adenocarcinoma, 22 squamous cell carcinoma, 15 
non-otherwise speciﬁable NSCLC), and samples from 18 patients non-
malignant inﬂammatory lung disease (7 chronic bronchitis, 7 interstitial 
lung disease, 4 sarcoidosis). NSCLC class prediction was performed 
using multivariate supervised between-group analysis (BGA). Predic-
tion accuracy was assessed by leave-one-out crossvalidation. Prediction 
of clinical outcome was based on Cox regression and a metagene-based 
approach followed by Kaplan-Meier analyses. The robustness of the 
identiﬁed metagene was tested by two-level cross-validation.
Results: NSCLC class prediction - The two major NSCLC classes 
were efﬁciently separated despite the proportion of tumor tissue of the 
biopsies was low in 17 samples (prediction accuracy 96%). In 19 sam-
ples the pathologist could not identify tumor cells (diagnosis was made 
with subsequent histology). In these samples the prediction accuracy 
was 43%. Roughly 70% of discriminative genes matched with previous 
reports, which validated the presence of tumor signals (squamous cell 
carcinoma: e.g. cytokeratins; adenocarcinoma: e.g. pulmonary-surfac-
tant proteins).
Clinical outcome prediction - NSCLC samples were scored using a 
metagene (Figure 1, left panel). This prognostic metagene was able 
to differentiate “high” and “low” risk outcomes within each of four 
NSCLC tumor stages (Figure 1, right panel). There was a signiﬁcant 
gain of outcome prediction when using this metagene compared with 
the staging information alone (p<0.001). Grading, age and sex were not 
associated with outcome.
Figure 1. Prediction of survival based on a prognostic metagene. The left 
panel shows the correlation between survival and metagene scores. Only 3 
out of 14 patients with a metagene score >75th percentile survived >1 year. 
The right panel shows Kaplan-Meier curves of the four NSCLC stages that are 
differentiated further into two subclasses based on the metagene scores. 
Conclusion: Our microarray-based approach shows that it is possible 
to use small lung or bronchial biopsies obtained by endoscopy to help 
assessing tumor class membership and to predict clinical outcome. 
Thus, this approach could be particularly useful for those NSCLC 
patients who do undergo neither surgery nor CT-guided biopsy proce-
dures. Microarray results were complementary to histopathology.
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Background: Activating epidermal growth factor receptor (EGFR) 
mutations in NSCLC tumors are associated with rapid and sustained 
clinical response to EGFR tyrosine kinase inhibitors (TKIs). Due to 
tumor heterogeneity, identiﬁcation of EGFR mutations using conven-
tional DNA sequencing approaches can be problematic. Tumor-speciﬁc 
mutations such as KRAS have been detected in shed tumor DNA in 
patient plasma (Kimura, Ann N Y Acad Sci, 2004), and the ability 
to detect EGFR mutations in patient plasma would have potentially 
signiﬁcant clinical utility. Here we describe the performance of an al-
lele-speciﬁc real-time PCR system utilizing Scorpion primers (provided 
by DxS, UK) to detect EGFR mutations in tumor tissue and plasma.
Methods: The sensitivity of this technique in terms of the ratio of 
mutant-to-wild-type genomic DNA and the minimum amount of DNA 
required for detection was determined using a dilution experiment. 
Genomic DNA from lung cancer cell lines containing either the exon 
21 L858R point mutation or the exon 19 E746-750 deletion was mixed 
with wild-type genomic DNA at ratios ranging from 1:2 to 1:10,000. 
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The presence of EGFR mutations was also determined in archival 
tumor material and/or plasma obtained from 39 consenting advanced 
stage NSCLC patients treated with EGFR-TKIs. 
Results: In cell line experiments, mutant DNA was detectable utilizing 
the Scorpion technology at concentrations as low as 25 pg, and at ratios 
as little as 0.1% of the total pool of genomic DNA. Of the 39 NSCLC 
patients, only tissue was available for evaluation in seven patients; two 
were positive both with the Scorpion primers and direct sequencing 
while the rest were wild-type. For 21 patients where only plasma was 
available, 6 mutations were detected with Scorpion primers, none of 
which were detectable by direct sequencing. EGFR mutations were 
identiﬁed in both plasma and tissue of two patients who were complete 
responders to EGFR-TKI therapy, only one of which was detectable by 
direct sequencing. Two additional mutations were found in the tissue 
but not plasma of patients currently undergoing treatment. Neither of 
these mutations was detectable by direct sequencing.
Conclusions: Allele-speciﬁc Scorpion technology is: 1) highly speciﬁc 
and sensitive for EGFR mutation analysis, 2) able to detect mutations 
not observable by direct sequencing in plasma and tissue, 3) capable 
of detecting mutations in shed tumor DNA in plasma and 4) may be 
suitable for monitoring response or detecting recurrence in advanced 
NSCLC patients. 
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Background: The presence of somatic mutations in epidermal growth 
factor receptor (EGFR) predicts the response of EGFR tyrosine kinase 
inhibitors (TKIs). It has been reported that exon 19 and 21 mutation 
correlates with the effectiveness and exon 20 mutation correlates with 
the resistance of EGFR-TKIs. It would be ideal if EGFR mutation 
can be detected by biopsy samples, since the majority of non-small 
cell lung cancer patients at the time of presentation are inoperable. 
We have reported the usefulness of endobronchial ultrasound guided 
transbronchial needle aspiration (EBUS-TBNA). EBUS-TBNA has a 
high sensitivity as well as speciﬁcity for mediastinal and hilar lymph 
node staging in patients with lung cancer. EBUS-TBNA is a real-time 
procedure that enables multiple biopsies with good histological cores. 
Methods: The purpose of this study was to develop and analyze 
the feasibility of detecting EGFR mutation in samples obtained by 
EBUS-TBNA. Fifty six patients with primary lung cancer diagnosed 
as metastatic adenocarcinoma in hilar and/or mediastinal lymph node 
by EBUS-TBNA were analyzed. We extracted DNA from parafﬁn 
embedded samples and investigated the EGFR mutation in exon 19 and 
21 using a newly developed Loop- Hybrid Mobility Shift Assay (LH-
MSA). The results were conﬁrmed by direct sequence method in the 
ﬁrst 46 cases. Furthermore we analyzed the exon 19 to 21 in 10 cases 
using LH-MSA.
Results: Out of the 56 cases, 53 cases contained tumor cells in re-
sliced parafﬁn embedded specimens and were analyzed. Thirty four 
patients (64.2%) were male. EGFR mutation was detected in 15 cases 
(30.2%); three cases were in-ﬂame deletion of exon 19, one case was 
point mutation of exon 20, and 12 cases were point mutation of exon 
21. 52.6% of the female population (10 out of 19 cases) showed EGFR 
mutation. Two cases with exon 21 point mutation were treated by ge-
ﬁtinib. A case with multiple mediastinal lymph node metastases along 
with malignant pericardial effusion showed a signiﬁcant decrease in 
size of the tumor two weeks after the administration of geﬁtinib and has 
been alive for 22 months.
Conclusions: EGFR mutation can easily be detected in metastatic 
lymph nodes sampled by EBUS-TBNA. EBUS-TBNA allows genetic 
evaluations of tumor cells within the lymph node and may provide 
us with indications for EGFR-TKI therapy before administration of 
EGFR-TKIs therapy in the near future. EBUS-TBNA samples will 
possibly provide other molecular biological information which will be 
useful for the treatment of advanced and recurrent lung cancer disease
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Background: In preclinical models, proteomic proﬁling has revealed 
that circulating platelets selectively take up tumor-derived angiogenesis 
regulatory proteins (J. Folkman et al. FASEB J 20:A414,2006). The 
aim of this study was to assess whether this novel function of platelets 
could be efﬁciently explored with proteomic proﬁling of the low mo-
lecular weight (LMW) proteome, and further reveal lung cancer (LC) 
speciﬁc markers. 
Methods: Blood samples (4-ml EDTA tubes) were collected from 
54 patients (29 with newly diagnosed advanced NSCLC and 25 with 
benign lung diseases) under the same conditions. Written informed 
consent was obtained from all patients. LC patients included 18 
adenocarcinomas, 7 squamous tumors, 2 large cell carcinomas and 2 
low differentiated NSCLC. The control group included 5 patients with 
hamartoma, 14 with non-speciﬁc lung inﬁltrate and 6 with diverse be-
